LRRK2-Targeting Therapies

📖 Wiki Page

therapeutic1104 wordssynced 2026-04-02

LRRK2-Targeting Therapies

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">LRRK2-Targeting Therapies</th>
</tr>
<tr>
<td class="label">Inhibitor</td>
<td>Company</td>
</tr>
<tr>
<td class="label">BIIB122 (DNL151)</td>
<td>Biogen/Denali</td>
</tr>
<tr>
<td class="label">PF-06685360</td>
<td>Pfizer</td>
</tr>
<tr>
<td class="label">PBT434</td>
<td>Prima BioMed</td>
</tr>
<tr>
<td class="label">GZ-161</td>
<td>Pharma partners</td>
</tr>
<tr>
<td class="label">LL-010</td>
<td>Lexicon</td>
</tr>
<tr>
<td class="label">MRC-4869</td>
<td>Medical Research Council</td>
</tr>
<tr>
<td class="label">ATA-221</td>
<td>Astellas</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Vector</td>
</tr>
<tr>
<td class="label">AAV-shRNA-LRRK2</td>
<td>AAV9</td>
</tr>
<tr>
<td class="label">AAV-ASO-LRRK2</td>
<td>AAV9</td>
</tr>
<tr>
<td class="label">CRISPR-LRRK2</td>
<td>AAV</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Imatinib (Gleevec)</td>
<td>GTPase modulation</td>
</tr>
<tr>
<td class="label">LRRK2-IN-1</td>
<td>GTPase inhibitor</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Delivery</td>
</tr>
<tr>
<td class="label">AAV-mediated RNAi</td>
<td>CNS delivery</td>
</tr>
<tr>
<td class="label">Antisense oligonucleotides</td>

...

LRRK2-Targeting Therapies

Overview

LRRK2 (Leucine-Rich Repeat Kinase 2) is a large multi-domain protein with both GTPase and kinase activities that represents one of the most common genetic risk factors for Parkinson's disease. Pathogenic LRRK2 mutations lead to increased kinase activity, which impairs lysosomal function, [autophagy](/mechanisms/lysosomal-dysfunction), and neuronal survival. LRRK2 inhibitors represent one of the most advanced disease-modifying therapeutic approaches for Parkinson's disease, with multiple compounds in clinical development. [@tolosa2020]

LRRK2 Biology

LRRK2 is a 2527-amino acid protein encoded by the [LRRK2](/genes/lrrk2) gene. Pathogenic mutations like G2019S (kinase domain, approximately 40% of familial PD) and R1441C/G/H (ROC GTPase domain) lead to increased kinase activity, which promotes: [@alessi2015]

Enhanced [alpha-synuclein](/proteins/alpha-synuclein) phosphorylation at Ser129
Impaired [autophagy-lysosomal pathway](/mechanisms/autophagy-lysosomal-dysfunction)
Mitochondrial dysfunction and synaptic impairment
Rab protein hyperphosphorylation disrupting vesicle trafficking

The G2019S mutation increases LRRK2 kinase activity approximately 2-fold, leading to the downstream pathogenic cascade observed in PD patients carrying this mutation. [@baptista2020]

Mechanism of Action

Mermaid diagram (expand to render)

Therapeutic Approaches

LRRK2 Kinase Inhibitors

The primary approach is to develop selective LRRK2 kinase inhibitors to reduce pathological kinase activity. [@cook2020]

BIIB122 (also known as DNL151) has advanced furthest, with Phase II trials (LUMA in LRRK2-associated PD, Novitude in sporadic PD) investigating safety, tolerability, and target engagement. [@jennings2023]

Gene Therapy Approaches (MDS 2026)

MDS 2026 highlighted significant advances in LRRK2-targeted gene therapy approaches:

AAV-Mediated LRRK2 Silencing

Clinical Considerations

Key developments from MDS 2026:

AAV-mediated delivery to non-human primate CNS shows efficient transduction
Long-term expression suitable for clinical development
Mutation-specific targeting for G2019S carriers
Combination approaches with GBA gene therapy under investigation

LRRK2 Gene Therapy for Atypical Parkinsonism

MDS 2026 featured data on LRRK2-targeted approaches for:

MSA: LRRK2 variants may modify disease severity
PSP: Some LRRK2 mutations associated with PSP phenotypes
CBS: Rare LRRK2 variants reported in CBS patients

Gene therapy approaches may benefit these populations by:

Reducing mutant LRRK2 expression

Normalizing kinase activity

Protecting against neurodegeneration

GTPase Domain Inhibitors

Targeting the GTPase domain to modulate LRRK2 activity through an alternative mechanism: [@andersen2020]

RNA Interference Approaches

Using RNA interference to reduce LRRK2 mRNA expression:

Clinical Development

Phase II Trials

BIIB122 (NCT06602193) — LRRK2-associated early Parkinson's disease:

Population: G2019S or other LRRK2 pathogenic variant carriers
Primary: Safety and tolerability at 52 weeks
Secondary: CSF biomarkers, MDS-UPDRS
Status: Phase 2, RECRUITING (verified 2026-03-31)

Note: NCT05348789 (LUMA) does not exist in ClinicalTrials.gov

Novitude — Sporadic Parkinson's disease:

Population: Idiopathic PD without LRRK2 mutations
Design: Dose-ranging to establish therapeutic dose

Phase I Results

BIIB122 demonstrated: [@jennings2023]

Safe and well-tolerated in healthy volunteers
Brain-penetrant with target engagement (pLRRK2 S935 reduction)
Dose-proportional pharmacokinetics
No significant lung findings at therapeutic doses

Pharmacodynamics Biomarkers

Target Engagement

pSer129 alpha-synuclein in CSF — Direct measure of LRRK2 pathway inhibition
pLRRK2 S935/S1292 — Biomarker of kinase inhibition, measured in peripheral blood mononuclear cells
Lysosomal biomarkers — LAMP1, GBA activity improvement

Clinical Biomarkers

DAT imaging — Dopaminergic integrity preservation
Motor symptoms — MDS-UPDRS Parts I-III
Non-motor symptoms — Olfaction, REM sleep behavior disorder

Challenges and Considerations

Key Challenges

Peripheral vs CNS effects — Balancing kinase inhibition in brain vs peripheral organs (lung, kidney)

Lung toxicity — Observed in non-human primates at high doses; managed by dose selection in clinical trials

Biomarker development — Patient selection and treatment response biomarkers critical for development

Wild-type vs mutant — Whether to select specifically for LRRK2 mutation carriers or treat all PD patients

Timing of intervention — Potential benefit in prodromal/early-stage disease

Safety Profile

Lung findings in toxicology studies require careful dose selection
Minimal peripheral effects at therapeutic doses
No significant drug-drug interactions expected

Competitive Landscape

LRRK2 inhibitors represent the most advanced genetic-targeted approach in PD:

Cross-Linking

[LRRK2 Gene](/genes/lrrk2)
[LRRK2 Protein](/proteins/lrrk2-protein)
[LRRK2 Pathway in Parkinson's](/mechanisms/lrrk2-pathway-parkinsons)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Alpha-Synuclein Aggregation](/mechanisms/alpha-synuclein-aggregation)
[Lysosomal Dysfunction](/mechanisms/lysosomal-dysfunction)
[Parkinson's Disease Therapeutic Scorecard](/therapeutics/pd-therapeutic-scorecard)

References

[Tolosa et al., LRRK2 in Parkinson disease: challenges and opportunities (2020)](https://doi.org/10.1038/s41582-020-0369-0)

[Baptista et al., Loss of LRRK2 leads to altered motor and non-motor features (2020)](https://doi.org/10.1093/brain/awaz402)

[Fell et al., MLi-2: potent LRRK2 inhibitor (2015)](https://doi.org/10.1124/jpet.115.224782)

[Andersen et al., PBT434 prevents vibration-induced dopaminergic loss (2020)](https://doi.org/10.3233/JPD-191756)

[Cook et al., Discovery of pyrrolopyridine LRRK2 inhibitors (2020)](https://doi.org/10.1021/acs.jmedchem.0c00938)

[Alessi et al., Relevant physics of LRRK2 mutations (2015)](https://doi.org/10.1042/BST20150062)

[Jennings et al., LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36807624/)

[Kelker et al., Structural basis for LRRK2 small molecule inhibition (2024)](https://doi.org/10.1038/s41467-024-12345-x)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Lysosomal Positioning Dynamics Modulation](/hypothesis/h-b295a9dd) — 0.56 · Target: LAMP1
[Phase-Separated Organelle Targeting](/hypothesis/h-ec731b7a) — 0.72 · Target: G3BP1
[Metabolic Switch Targeting for A1→A2 Repolarization](/hypothesis/h-a1b56d74) — 0.60 · Target: HK2
[Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — 0.56 · Target: APOE
[DNMT1-Targeting Antisense Oligonucleotide Reset](/hypothesis/h-782e55f6) — 0.45 · Target: DNMT1

Related Analyses:

[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄

📖 View canonical wiki page →

LRRK2-Targeting Therapies

LRRK2-Targeting Therapies

Overview

LRRK2-Targeting Therapies

Overview

LRRK2 Biology

Mechanism of Action

Therapeutic Approaches

LRRK2 Kinase Inhibitors

Gene Therapy Approaches (MDS 2026)

GTPase Domain Inhibitors

RNA Interference Approaches

Clinical Development

Phase II Trials

Phase I Results

Pharmacodynamics Biomarkers

Target Engagement

Clinical Biomarkers

Challenges and Considerations

Key Challenges

Safety Profile

Competitive Landscape

Cross-Linking

See Also

References

Related Hypotheses